Scholz, S.* ; Koerber, F. ; Meszaros, K.* ; Fassbender, R.M.* ; Ultsch, B.* ; Welte, R.R.* ; Greiner, W.*
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
Vaccine 37, 1692-1701 (2019)
Ghasemi, A.* ; Mohammad, N.* ; Mautner, J. ; Taghipour Karsabet, M.* ; Amani, J.* ; Ardjmand, A.* ; Vakili, Z.*
Immunization with a recombinant fusion protein protects mice against Helicobacter pylori infection.
Vaccine 36, 5124-5132 (2018)
Beyerlein, A. ; Strobl, A.N.* ; Winkler, C. ; Carpus, M. ; Knopff, A. ; Donnachie, E.* ; Ankerst, D.P.* ; Ziegler, A.-G.
Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: Results from prospective cohort data.
Vaccine 35, 1735-1741 (2017)
Link, E.K.* ; Brandmüller, C.* ; Suezer, Y.* ; Ameres, S. ; Volz, A.* ; Moosmann, A. ; Sutter, G.* ; Lehmann, M.H.*
A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells.
Vaccine 35, 5131-5139 (2017)
Backes, S. ; Jager, C. ; Dembek, C.J. ; Kosinska, A. ; Bauer, T. ; Stephan, A.-S. ; Dišlers, A.* ; Mutwiri, G.* ; Busch, D.H. ; Babiuk, L.A.* ; Gasteiger, G. ; Protzer, U.
Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
Vaccine 34, 923-932 (2016)
Ghasemi, A.* ; Jeddi-Tehrani, M.* ; Mautner, J. ; Salari, M.H.* ; Zarnani, A.H.*
Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection.
Vaccine 33, 5532-5538 (2015)
Ghasemi, A.* ; Jeddi-Tehrani, M.* ; Mautner, J. ; Salari, M.H.* ; Zarnani, A.H.*
Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection.
Vaccine 32, 6659-6666 (2014)
von Sonnenburg, F.* ; Perona, P.* ; Darsow, U. ; Ring, J. ; von Krempelhuber, A.* ; Vollmar, J.* ; Roesch, S.* ; Baedeker, N.* ; Kollaritsch, H.* ; Chaplin, P.*
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
Vaccine 32, 5696-5702 (2014)
Buchmann, P.* ; Dembek, C.J. ; Kuklick, L.* ; Jager, C.* ; Tedjokusumo, R. ; von Freyend, M.J.* ; Drebber, U.* ; Janowicz, Z.* ; Melber, K.* ; Protzer, U.
A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in Hepatitis B Virus (HBV) transgenic mice.
Vaccine 31, 1197-1203 (2013)
Braeckman, T.* ; van Herck, K.* ; Jilg, W.* ; Bauer, T.* ; van Damme, P.*
Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory.
Vaccine 30, 4757-4761 (2012)
Farag, M.M.S.* ; Tedjokusumo, R. ; Flechtenmacher, C.* ; Asen, T. ; Stremmel, W.* ; Müller, M.* ; Protzer, U. ; Weigand, K.*
Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
Vaccine 30, 6034-6039 (2012)
Schlosser, E.* ; Mueller, M.* ; Fischer, S.* ; Basta, S.* ; Busch, D.H. ; Gander, B.* ; Groettrup, M.*
TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses.
Vaccine 26, 1626-1637 (2008)
Schulze, K.* ; Staib, C. ; Schatzl, H.M.* ; Ebensen, T.* ; Erfle, V. ; Guzman, C.A.*
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Vaccine 26, 6678-6684 (2008)
Antonis, A.F.G.* ; van der Most, R.G.* ; Suezer, Y.* ; Stockhofe-Zurwieden, N.* ; Daus, F.* ; Sutter, G. ; Schrijver, R.S.*
Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
Vaccine 25, 4818-4827 (2007)
El-Gogo, S.* ; Staib, C.* ; Meyr, M.* ; Erfle, V. ; Sutter, G. ; Adler, H.
Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
Vaccine 25, 3934-3945 (2007)
Hahn, U.K.* ; Aichler, M.* ; Boehm, R.* ; Beyer, W.*
Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep.
Vaccine 24, 4595-4597 (2006)
Meyer, P. ; Menzel, M. ; Muellinger, B.* ; Weber, N. ; Haeussinger, K. ; Ziegler-Heitbrock, L.
Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease.
Vaccine 24, 5832-5838 (2006)
Menzel, M.* ; Muellinger, B.* ; Weber, N. ; Häussinger, K. ; Ziegler-Heitbrock, L.
Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers.
Vaccine 23, 5113-5119 (2005)
Olszewska, W.* ; Suezer, Y. ; Openshaw, P.J.M.*
Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
Vaccine 23, 215-221 (2004)
Welte, R. ; van den Dobbelsteen, G.* ; Bos, J.M.* ; de Melker, H.* ; van Alphen, L.* ; Spanjaard, L.* ; Rümke, H.C.* ; Postma, M.J.*
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
Vaccine 23, 470-479 (2004)
Cosma, A. ; Nagaraj, R. ; Bühler, S.* ; Hinkula, J.* ; Busch, D.H.* ; Sutter, G. ; Goebel, F.D.* ; Erfle, V.
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals.
Vaccine 22, 21-29 (2003)
Stittelaar, K.J.* ; Gruters, R.A.* ; Schutten, M.* ; van Baalen, C.A.* ; van Amerongen, G.* ; Cranage, M.* ; Liljeström, P.* ; Sutter, G. ; Osterhaus, A.D.M.E.*
Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.
Vaccine 20, 2921-2927 (2002)
Nilsson, C.* ; Mäkitalo, B.* ; Berglund, P.* ; Bex, F.* ; Liljeström, P.* ; Sutter, G. ; Erfle, V. ; Ten Haaft, P.* ; Heeney, J.* ; Biberfeld, G.* ; Thorstensson, R.*
Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.
Vaccine 19, 3526-3536 (2001)
Collings, A.* ; Pitkänen, J.* ; Strengell, M.* ; Tähtinen, M.* ; Lagerstedt, A.* ; Hakkarainen, K.* ; Ovod, V.* ; Sutter, G. ; Ustav, M.* ; Ustav, E.* ; Männik, A.*
Humoral and cellular immune responses to HIV-1 Nev in mice DNA-immunised with non- replicating or self-replicating expression vectors.
Vaccine 18, 460-467 (2000)
Osterhaus, A.D.* ; van Baalen, C.A.* ; Gruters, R.A.* ; Schutten, M.* ; Siebelink, C.H.J.* ; Hulskotte, E.G.J.* ; Tijhaar, E.J.* ; Randall, R.E.R.* ; van Amerongen, G.* ; Fleuchaus, A.G. ; Erfle, V. ; Sutter, G.
Vaccination with Rev and Tat against AIDS.
Vaccine 17, 2713-2714 (1999)
von Brunn, A.  ; Reichhuber, C. ; Brand, M. ; Bechowsky, B. ; Gürtler, L. ; Eberle, J. ; Kleinschmidt, A. ; Erfle, V. ; Schödel, F.
The Principal Neutralizing Determinant (V3) of HIV-1 Induces HIV-1-neutralizing Antibodies upon Expression on HBcAg Particles.
Vaccine 93 (1993)